Chronic prostatitis is a common and difficult to treat disease in urology, accounting for about 25% of adult male patients’ diseases in urology clinics. The clinical characteristics are complex etiology, variable symptoms, prolonged course and high recurrence rate, which seriously affects the quality of life of patients and causes a huge economic burden to public health care. The cause and pathogenesis of chronic non-bacterial prostatitis is unknown, and there are several theories, Nickel believes that chronic prostatitis should be a multifactorial disease, in which there are initiating factors, mediating factors, and effect factors that finally cause clinical symptoms. The microbial infection and the immune factor are closely related. The theory of urinary reflux in the prostate is one of the main theories. The local inflammatory response of the prostate and the systemic phytonadic dysfunction and psychological disorders can increase the local α1-AR excitability and upregulate the expression of α1-AR subtypes in the posterior urethra, which increases the urethral pressure in the prostate during urination and makes it easy for urine to reflux into the prostatic ducts, which can cause chemical prostatitis, which is not only an important pathogenic factor for type III CP, but also brings pathogens into the prostate during urinary reflux. It is not only an important pathogenic factor for type III CP, but also brings pathogens into the prostate gland during urinary reflux, which is an important route of infection for type I and II prostatitis. This results in a cascade reaction. This speculation is widely accepted based on basic studies of α1-AR changes in the lower urinary tract in prostate enlargement, but so far there is a lack of support from experimental studies directly derived from chronic prostatitis (CP). Currently, there is a wide range of drugs or methods for the treatment of CP, of which antibiotics and adrenergic receptor (α-AR) blockers are the most commonly used drugs. According to the theory that chronic prostatitis is a “chemical prostatitis” caused by urinary reflux due to functional obstruction of the lower urinary tract, removing functional obstruction of the lower urinary tract is the key to treating the disease. The alpha-blockers are used in the treatment of chronic prostatitis. By blocking the bladder neck and urethral alpha1-AR, the urethral spasm tends to be relieved, the pressure in the urethra decreases, and the reflux of urine into the prostatic ducts and alveoli is terminated or reduced, so that the “chemical” irritation of the prostate caused by uric acid in the urine disappears. The painful symptoms of prostate pain caused by the “chemical” irritation of uric acid in the urine disappear and are somewhat effective. However, in a large randomized placebo-controlled multicenter study conducted by the National Institutes of Health Chronic Prostatitis Cooperative Research Network (NIH-CPCRN) and funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIH-NIDDK), not by the drug companies, 6 weeks of tamsulosin treatment was similar to placebo. European Urology accordingly concluded that alpha1-AR blockers were ineffective in the treatment of type III prostatitis in its 2009 revised guidelines.